Methods, compositions, and devices for supplying dietary fatty acid needs
US-12059391-B2 · Aug 13, 2024 · US
Method of treatment of obesity
US10925849B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10925849-B2 |
| Application number | US-201716088312-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2017 |
| Priority date | Mar 15, 2016 |
| Publication date | Feb 23, 2021 |
| Grant date | Feb 23, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating obesity and overweight, comprising administering to a subject in need thereof a composition comprising lauric acid and 3-(4-((4-fluoro-4′-methyl-[1,1′-biphenyl]-2-yl)methoxy)phenyl)propanoic acid (TUG891), wherein the composition is a delayed release formulation for release in the distal small intestine and large intestine. 2. A method of treating obesity, comprising administering to a subject in need thereof a composition comprising lauric acid and 3-(4-((4-fluoro-4′-methyl-[1,1′-biphenyl]-2-yl)methoxy)phenyl)propanoic acid (TUG891), wherein the composition is a delayed release formulation for release in the distal small intestine and large intestine. 3. The method according to claim 1 , wherein the composition further comprises an amino acid.
Assignees
Inventors
Classifications
having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} · CPC title
Linaceae (Flax family), e.g. Linum · CPC title
Anorexiants; Antiobesity agents · CPC title
- A61K31/20Primary
having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title
- A61K31/01Primary
Hydrocarbons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10925849B2 cover?
- The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.
- Who is the assignee on this patent?
- Univ London Queen Mary
- What technology area does this patent fall under?
- Primary CPC classification A61K31/20. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).